As mentioned above, CCNE1 amplification is prevalent in primary PROC and WEE1 kinase inhibitors show a manageable toxicity profile and encouraging efficacy in epithelial ovarian cancer harboring CCNE1 amplification.23 This evidence concerns the gene CCNE1 and ovarian carcinoma.